CytomX Therapeutics (CTMX) is scheduled to report Q1 earnings on May 11, 2026. Analysts estimate EPS of $-0.12 and quarterly revenue of $4.22M.

In the most recent quarter (Q4), CytomX Therapeutics reported EPS of $-0.22, missing estimates of $-0.09 by 1.44%. Revenue came in at $663.00K, missing the estimate of $7.33M by 0.91%.

CytomX Therapeutics has missed EPS estimates in 2 consecutive quarters.

Over the last 4 quarters, CytomX Therapeutics has averaged an EPS surprise of 1.19% and a revenue surprise of 0.47%.